Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$106.8m

Fortress Biotech Future Growth

Future criteria checks 2/6

Fortress Biotech's earnings are forecast to decline at 49% per annum while its annual revenue is expected to grow at 35.1% per year. EPS is expected to decline by 42.6% per annum.

Key information

-49.0%

Earnings growth rate

-42.61%

EPS growth rate

Biotechs earnings growth25.6%
Revenue growth rate35.1%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Aug 2025

Recent future growth updates

Recent updates

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
User avatar

FDA Approval Will Open $1 Billion Dermatology Market

Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Earnings and Revenue Growth Forecasts

NasdaqCM:FBIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027145-82N/AN/A1
12/31/2026121-53N/AN/A3
12/31/202585-27N/AN/A3
6/30/202559-24-95-80N/A
3/31/202558-51-89-74N/A
12/31/202458-56-95-80N/A
9/30/202482-58-102-102N/A
6/30/202483-49-100-99N/A
3/31/202485-63-113-110N/A
12/31/202385-69-136-128N/A
9/30/202362-86-150-141N/A
6/30/202363-104-176-168N/A
3/31/202364-100-182-176N/A
12/31/202276-95-202-179N/A
9/30/202278-97-196-170N/A
6/30/202282-93-181-149N/A
3/31/202281-74-179-142N/A
12/31/202169-65-133-117N/A
9/30/202164-38-113-98N/A
6/30/202153-33-110-101N/A
3/31/202144-43-89-83N/A
12/31/202046-47-91-84N/A
9/30/202043-57-99-88N/A
6/30/202043-54-92-81N/A
3/31/202043-54-102-92N/A
12/31/201937-40-104-95N/A
9/30/201934-45-98-92N/A
6/30/201930-51-106-101N/A
3/31/201927-53N/A-96N/A
12/31/201827-73N/A-99N/A
9/30/2018-107-61N/A-98N/A
6/30/2018-65-69N/A-98N/A
3/31/2018-22-72N/A-98N/A
12/31/201717-65N/A-81N/A
9/30/2017155-74N/A-78N/A
6/30/2017109-60N/A-62N/A
3/31/201761-55N/A-46N/A
12/31/201616-55N/A-46N/A
9/30/20164-50N/A-35N/A
6/30/20163-55N/A-31N/A
3/31/20161-49N/A-30N/A
12/31/20151-48N/A-20N/A
9/30/20151-40N/A-17N/A
6/30/20151-27N/A-14N/A
3/31/20151-25N/A-12N/A
12/31/2014N/A-20N/A-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FBIO's revenue (35.1% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: FBIO's revenue (35.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/10 13:33
End of Day Share Price 2025/09/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fortress Biotech, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Stephen V. ByrneBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.